U.S. Considers Allowing Most Pharma Licensing Deals With China
The U.S. Treasury Department is reportedly working on new rules that would allow biopharmaceutical companies to maintain most of their licensing agreements for drugs developed in the United States, even if they invest in projects within China. According to Reuters sources familiar with the matter, these proposed regulations aim to balance national security concerns and economic interests by permitting a wide range of pharmaceutical collaborations. The move is seen as an effort to avoid overly restrictive policies that could hinder innovation or global competitiveness while still addressing potential risks associated with foreign investment in sensitive sectors. The outcome will likely influence how U.S.-based biopharma firms operate internationally, particularly regarding technology transfer and joint ventures involving Chinese partners.
